{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360574094499791104.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1111/j.1478-3231.2010.02386.x"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1478-3231.2010.02386.x"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1478-3231.2010.02386.x"}}],"dc:title":[{"@value":"Treatment of HBeAg‐negative chronic hepatitis B with pegylated interferon"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:title>Abstract</jats:title><jats:p>Serum HBeAg‐negative chronic hepatitis B, which is usually a late stage of chronic hepatitis B virus infection, is difficult to treat, because it is characterized by fluctuating alanine transaminase values resulting in hepatitis flares, accelerated progression to cirrhosis and liver cancer. Antiviral treatment, either long‐term nucleot(s)ide therapy or 1‐year administration of pegylated interferon (PEG‐IFN), is therefore necessary to limit the course of the disease. A sustained virological response to PEG‐IFN is achieved in approximately 1/4 of the patients, with significant rates of HBsAg seroclearance. While waiting for the results of several studies whose goal is to improve the long‐term efficacy of PEG‐IFN, the treatment strategy can be optimized by a careful selection of patients, discontinuation of PEG‐IFN as early as possible in primary non‐responders and extended therapy (up to 96 weeks) in responders.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380574094499791105","@type":"Researcher","foaf:name":[{"@value":"Pietro Lampertico"}]},{"@id":"https://cir.nii.ac.jp/crid/1380574094499791106","@type":"Researcher","foaf:name":[{"@value":"Mauro Viganò"}]},{"@id":"https://cir.nii.ac.jp/crid/1380574094499791104","@type":"Researcher","foaf:name":[{"@value":"Massimo Colombo"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"14783223"},{"@type":"EISSN","@value":"14783231"}],"prism:publicationName":[{"@value":"Liver International"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2011-01","prism:volume":"31","prism:number":"s1","prism:startingPage":"90","prism:endingPage":"94"},"reviewed":"false","dc:rights":["http://onlinelibrary.wiley.com/termsAndConditions#vor"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1478-3231.2010.02386.x"},{"@id":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1478-3231.2010.02386.x"}],"createdAt":"2011-01-04","modifiedAt":"2023-09-13","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Hepatology","dc:title":"Hepatology"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679770662656","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"The efficacy of sequential treatment with lamivudine and alpha-interferon in anti-HBe-negative chronic hepatitis B patients -Examination of HBsAg seroclearance-"},{"@language":"ja","@value":"HBe抗原陰性B型慢性活動性肝炎に対するSequential療法の有用性―HBs抗原陰性化への検討―"},{"@language":"ja-Kana","@value":"HBe コウゲン インセイ Bガタ マンセイ カツドウセイ カンエン ニ タイスル Sequential リョウホウ ノ ユウヨウセイ : HBs コウゲン インセイカ エ ノ ケントウ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1111/j.1478-3231.2010.02386.x"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.720_references_DOI_7vsonNSMMOvJvEV9UdbbBY7RQi8"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_7vsonNSMMOvJvEV9UdbbBY7RQi8"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_7vsonNSMMOvJvEV9UdbbBY7RQi8"}]}